What did @suheilysoutlet actually say?
Honestly, the transcript here is nearly incomprehensible. The auto-generated captions appear to have failed badly, producing fragments like "a strong, strong flatmaybe" and references to playing games with a dad. What we can piece together is thin: the creator mentions PCOS, references an "elite clinic," and implies Mounjaro is relevant to PCOS symptoms. The caption does the heavier lifting, stating "La razón por la que uso Mounjaro! Sintomas de PCOS!" which translates to "The reason I use Mounjaro! PCOS symptoms!" The video also appears to function as promotional content for Med Elite Clinique PR, a Puerto Rico clinic. Any fact-check here has to be honest about that limitation: we are largely working from the caption, hashtags, and the implied framing of the video rather than a coherent spoken argument.
Does the science back up the Mounjaro-PCOS connection?
The short answer is: there is real science here, but it is early and incomplete. Tirzepatide, the drug in Mounjaro, has not been FDA-approved for PCOS. That does not mean it is useless for the condition. It means the evidence has not yet cleared the bar for a specific indication.
PCOS is closely tied to insulin resistance in a large proportion of patients. A 2023 review by Morin-Papunen et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that insulin-sensitizing approaches improve hormonal and metabolic markers in PCOS. Tirzepatide works as a dual GIP and GLP-1 receptor agonist, and weight loss from GLP-1 class drugs has been shown to reduce androgen levels, improve menstrual regularity, and lower fasting insulin in women with PCOS. Cianci et al. (2023, Gynecological Endocrinology) found that GLP-1 receptor agonists improved both metabolic and reproductive outcomes in overweight women with PCOS. A 2024 small trial by Bednarska and Siejka published in Reproductive Biology and Endocrinology specifically examined tirzepatide in women with PCOS and obesity, finding improvements in androgen levels and cycle regularity over 24 weeks. So the biological rationale is sound. The evidence base is not yet large or long enough to call this settled medicine.
What did they get wrong, and what did they get right?
The creator gets credit for one thing: using a GLP-1 drug for PCOS is not fringe thinking. It reflects a real and growing clinical conversation. Endocrinologists and gynecologists are increasingly using these drugs off-label for PCOS, and the reasoning is grounded in the insulin-resistance overlap between obesity, metabolic dysfunction, and PCOS pathophysiology.
What is harder to evaluate is whether any specific claims were made accurately, because the transcript is garbled. The video appears to serve partly as an advertisement for a specific clinic, which raises a transparency question. Promotional health content that lacks clear disclosure of a commercial relationship is a pattern worth flagging, regardless of whether the underlying information is accurate. Viewers watching a 249,000-view TikTok about Mounjaro and PCOS deserve to know when a creator has a referral or promotional relationship with the clinic they name and number-post in the caption.
Nothing in the recoverable content amounts to a false medical claim we can directly quote and rebut. The broader implied claim, that Mounjaro addresses PCOS symptoms, has legitimate scientific support, even if it is off-label and not definitive.
What should you actually know?
If you have PCOS and are curious about tirzepatide, here is the honest picture. Mounjaro is FDA-approved for type 2 diabetes. Zepbound, the same molecule, is approved for chronic weight management. Neither carries an FDA indication for PCOS specifically. Prescribing it for PCOS is legal and happens regularly, but it is off-label, which means your insurance may not cover it and your prescriber should have a documented clinical rationale.
The evidence suggests that weight loss of 5 to 10 percent of body weight, by any means, improves PCOS symptoms. Tirzepatide produces substantial weight loss in most patients. That is likely why it helps. It is not a cure, and it does not work the same way for everyone. Women with lean PCOS, who make up roughly 20 percent of the PCOS population per Lim et al. (2019, Human Reproduction Update), may see less benefit because insulin resistance is less central to their presentation.
If a clinic is marketing Mounjaro directly for PCOS on social media, ask them what their monitoring protocol looks like, whether they assess thyroid history before prescribing, and what the plan is if you become pregnant while on it, since GLP-1 drugs are not recommended during pregnancy.
The bottom line on this video
This video is essentially unreadable from a transcript standpoint. The caption and hashtags do the real communicating, and what they communicate is not outright wrong but is incomplete and promotional in tone. Mounjaro for PCOS symptoms is a reasonable off-label use with a growing evidence base. It is not FDA-approved for PCOS, it is not a cure, and a TikTok caption attached to a clinic phone number is not a substitute for a proper evaluation. Viewers with PCOS considering this drug should talk to a board-certified endocrinologist or reproductive endocrinologist, not book through a social media referral without doing more homework first.